News

Wellington invests in SIRS Therapeutics to develop FX06 for treatment of ARDS in COVID-19 patients in collaboration with F4 Pharma

Details

Wellington Partners today announced a seed investment into newly founded SIRS Therapeutics, Munich, Germany. With the investment, SIRS has secured the joint ownership with Austrian F4 Pharma of all rights on FX06, a fibrin-derived peptide for treatment of patients with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS), including patients with underlying COVID-19 infection. 

First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01

Details

ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta T cell-activatingmonoclonal antibody targeting the extracellular domain of Butyrophilin 3A. EVICTION (EValuation of ICT01 in Immuno-ONcology) is a first-in-human, two-part, open-label clinical trial to assess the safety, tolerability and activity of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced, relapsed/refractory cancer, including both solid and hematologic tumors that express BTN3A. 

Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models

Details

Nature Biotechnology has published a study demonstrating Carisma's foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens. 

  1. Karl Naegler joins Wellington Partners as Managing Partner
  2. Wellington Partners participates in $53 Million Series B financing at ImCheck
  3. Wellington Partners participates in $100 Million Series B financing at eGenesis
  4. UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
© Wellington Partners, 2020.